New antibody combo takes on Hard-to-Treat myeloma
NCT ID NCT07210047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink or control the cancer. Participants receive HuL001 injections every two weeks, take lenalidomide for 21 days each month, and take dexamethasone weekly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HuL001 (an antibody) combined with lenalidomide and dexamethasone
What this could lead to
If this works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply to everyone. The combination may cause side effects or fail to control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Far Eastern Memorial Hospital
Taipei, Taiwan